狄诺塞麦可治疗什么病症呢？

What conditions can be treated? Denosumab is suitable for (1) bone metastases from solid tumors: it is suitable for preventing bone-related events in patients with bone metastases from solid tumors. (2) Important limitations of use: Not suitable for prevention of bone-related events in patients with multiple myeloma. 

Denosumab is a RANK ligand (RANKL) inhibitor with a different mechanism of action than currently approved drugs that reduce skeletal complications of tumors. It is a fully humanized monoclonal antibody (IgG2 monoclonal antibody) that specifically targets receptor activator of nuclear factor-κB ligand (RANKL). It prevents RANKL from binding to its receptor substances, inhibits osteoclast activation and development, reduces bone resorption, and increases bone density.

Denosumab is an injection that requires subcutaneous injection of 120 mg into the upper arm, upper thigh, or abdomen once every 4 weeks. Calcium and vitamin D are given when treatment or prevention of hypocalcemia is required.

Hypocalcemia must be corrected before denosumab therapy can be initiated. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.

Patients who are concurrently taking immunosuppressants or have compromised immune systems may be at increased risk of serious infections, and physicians need to fully consider the benefit-risk ratio before prescribing denosumab to such patients. Physicians should evaluate the need for continued denosumab treatment in patients who develop serious infections while taking denosumab.

On May 27, 2019, Amgen China announced that denosumab injection () has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or that may result in severe functional disability after surgical resection, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and body weight >45 kg).